Bristol Myers Squibb BMY-0.64%decrease; red down pointing triangle reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for ...
San Diego-based clinical-stage biotechnology company Mirador Therapeutics Inc. closed a $250 million Series B financing in the third quarter of 2025. The financing included new investment from funds ...
Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs. The company posted ...
Deciduous Therapeutics is developing a novel class of immuno-therapies designed to systemically clear senescent cells and to treat co-morbidities of aging. The gradual accumulation in tissues and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results